Skip to content
2000
Volume 12, Issue 3
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Tuberculosis caused by Mycobacterium tuberculosis has emerged as the biggest curse of our time causing significant morbidity and mortality. Increasing resistance in mycobacterium to existing drugs calls for exploration of metabolic pathways for finding novel drug targets and also for prioritization of known drug targets. Recent advances in molecular biology, bioinformatics and structural biology coupled with availability of M. tuberculosis genome sequence have provided much needed boost to drug discovery process. This review provides a glimpse of attractive drug targets for development of anti-mycobacterial drug development.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557511209030187
2012-03-01
2024-12-24
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557511209030187
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test